Supriya LifescienceQ2 FY25

Supriya Lifescience Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹620.65P/E: 28.1Market Cap: ₹5.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Revenue expected to be higher in H2 FY25 compared to H1, with new product launches in Q3 gaining traction in non-regulated markets.
  • Whey protein project awaiting FSSAI license, expected by end of Q3, adding to revenue.
  • CMO/CDMO opportunities, particularly in formulation and API advanced intermediates, expected to start commercial revenue from Q4 FY25 or Q1 FY26.
  • Ambernath formulation contract manufacturing facility to begin revenue generation from Q4 FY25 or Q1 FY26.
  • Base case revenue target for FY27 is Rs. 1,000 crore, with potential upside to Rs. 1,200 crore due to higher utilization and new product traction.
  • New product launches expected to contribute around 15% of topline in 2 years.
  • Continued strong growth in regulated markets including LATAM, Europe, and North America.
  • Capacity expansion (Module E and Ambernath) expected to reach full utilization by end FY27, supporting 20%+ year-on-year revenue growth.

See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • Currently, Supriya Lifescience Limited is following a conservative borrowing approach, primarily using letters of credit and bank guarantees without tapping into working capital limits.
  • For the current year, CAPEX plans are focused on completing module E and the Ambernath facility, with about Rs. 100 crore planned for repairs of modules A, B, and C over phases.
  • There is no immediate indication of new debt or equity fundraising planned; next major expansion at Patalganga is considered 2.5 to 3 years down the line.
  • No mention of any new fundraising through equity or debt in the near term during the conference.
  • The company seems focused on organic growth and efficient use of existing financial resources while maintaining a strong financial position with a very low debt-to-equity ratio of 0.01.

See what Supriya Lifescience management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Current year CAPEX focuses on completing Module E and Ambernath facility.
  • Planned maintenance CAPEX for existing modules A, B, and C, estimated around Rs. 100 crore over phases.
  • No major CAPEX beyond this is anticipated in the near term.
  • Next significant expansion wave likely in 2.5 to 3 years, targeting Patalganga site.
  • Module E expansion adds about 400 KL capacity; Ambernath adds about 70 KL, totaling approx. 1,020 KL capacity.
  • Commercial production from Module E began in Q3; full utilization expected by end of FY27.
  • Operating expenses related to new facilities will increase by a few crores per quarter due to staffing and power costs but offset partially by solar power savings.

Track Supriya Lifescience — get its next earnings analysis in your feed

How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSupriya Lifescience
Rev 3Mar 3

How does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →